Regeneron Pharmaceuticals Inc. stormed onto the wet age-related macular degeneration (AMD) market with second quarter sales of Eylea (aflibercept injection) increasing 57 percent compared to their first quarter. The drug competes with Roche AG's Lucentis (ranibizumab) and off-label use from Avastin (bevacizumab).